Prevalence of HIV-Associated Metabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda

Table 2

Characteristics of patients initiated on stavudine- and zidovudine-based regimens.

Characteristics	Stavudine (𝑁=208)	Zidovudine (𝑁=215)	𝑃 value
Gender, male. 𝑁 (%)	72 (34.6)	96 (44.6)	0.035
Age, (5 years), median (IQR)	38 (33–43)	39 (34–46)	0.131
ART duration (years), median (IQR)	2.5 (1.8–2.9)	2.7 (1.8–3.3)	0.016
Initial CD4+ counts, median (IQR)	94 (30.5–171)	89 (38–166)	0.888
Initial body weight (Kg), median (IQR)	53.8 (48.3–61.5)	54 (48–60)	0.784
Peak body weight, median (IQR)	63 (57–71)	63 (57–68)	0.387
BMI >25 at study enrolment	57 (27.4)	56 (26.1)	0.752
Systolic blood pressure (mmHg), median (IQR)	120 (110–130)	110 (110–120)	<0.001
Hypertension, 𝑁 (%)*	33 (15.9)	16 (7.4)	0.007
CD4 at study enrolment >200 cells/μL	175 (85.0)	153 (72.5)	0.002
Abnormal waist to hip ratio^+	0.94 (0.88–0.99)	0.91 (0.88–0.95)	<0.001
Family history of hypertension, 𝑁 (%)	90 (43.7)	66 (30.7)	0.006
Family history diabetes mellitus, 𝑁 (%)	42 (20.4)	34 (15.8)	0.223
Lipodystrophy, 𝑁 (%)	74 (35.8)	14 (6.7)	<0.001
WHO stage III and IV, 𝑁 (%)	151 (72.6)	166 (77.2)	0.274

𝑁: number; IQR: interquartile range; WHO: World Health Organization; ART: antiretroviral treatment; BMI: body mass index.
*Hypertension defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.
⁺Waist to hip ratio was categorized into abnormal if the value was >0.94 for males and >0.8 for females.